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a  b  s  t  r  a  c  t
INTRODUCTION:  Pancreatic  ductal  adenocarcinoma  (PDAC)  with  peritoneal  metastases  (PM)  has  a
dismal  prognosis  and  palliative  systemic  chemotherapy,  which  represents  the  standard  treatment
option,  has  significant  pharmacokinetics  limitations  and  low  efficacy.  Pressurized  intraperitoneal  aerosol
chemotherapy  (PIPAC)  is  a  new  method  of drug  delivery  that is  expected  to maximize  exposure  of
peritoneal  nodules  to  antiblastic  agents.  A  combination  of systemic  chemotherapy  and  PIPAC  may  be
valuable.
PRESENTATION  OF CASE:  A 55  years  old  male  affected  by PDAC  with synchronous  PM  underwent  a multi-
modal  treatment  comprising  systemic  chemotherapy  and  PIPAC  without  any  procedural-related  adversePeritoneal metastases
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Carcinomatosis
events.  Tumor  genomic  profiling  evaluation  from  peritoneal  biopsies  addressed  further  tailored  systemic
chemotherapy.
DISCUSSION:  The  presented  case  illustrates  the  possibility  of adding  PIPAC  to  systemic  chemotherapy
with  a  fair  tolerance  profile  and  good  quality  of  life  while  allowing  monitoring  of  therapy-response  and
tailoring  of the  antiblastic  treatment.















Pancreatic ductal adenocarcinoma (PDAC) is an aggressive neo-
plasm carrying a high metastatic potential and a 5-year survival
rate of 5–7% [1].
Surgery represents the only curative alternative but just 15%
of patients undergo primary tumor resection which is often asso-
ciated with severe complications requiring long-term recovery
[2]. Indeed, at the time of diagnosis, the vast majority of cases
already developed a locally advanced disease, distant or peritoneal
metastases (PM) [3]. Furthermore, the recurrence rate is nearly
80% within the first two years after surgery, and about half of
these patients show peritoneal relapse [4,5]. While peritoneal dis-
ease constitutes a substantial burden for PDAC patients, systemic
chemotherapy represents the only option available in such cases,
leading to a median survival of 6–11 months [6–9].
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The efficacy of intravenous chemotherapy may  be impaired by
carce vascularization and reduced blood supply of peritoneal nod-
les [10]. Thus, the idea of intraperitoneal chemotherapy has a
trong rationale [11]. The need to improve pharmacokinetics lim-
tation of systemic chemotherapy prompted research efforts to
evelop new treatment alternatives.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
merged in the last few years as a novel method of drug admin-
stration with encouraging results in the treatment of PM of
everal origins [12]. Based on the aerosolization of drugs during
aparoscopy, PIPAC optimizes penetration of chemotherapy agents
nto peritoneal tumor implants with favorable pharmacokinetics
nd biodistribution profiles [13].
Previous experiences on PIPAC for peritoneal diffusion from
DAC reported a relevant antitumoral activity with reassuring
afety and toxicity profiles with the use of the combination of cis-
latin and doxorubicin (PIPAC-CD) or oxaliplatin [8,14,15].
Here we  describe our first application of PIPAC-CD and systemic
hemotherapy for PM of pancreatic origin, in a referral center for
eritoneal surface disease.
This case was  prepared and reported in line with the SCARE
riteria [16].
 an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Abdomen CT scan before (A) and after (B) systemic chemotherapy with FOLFIRINOX. Red arrow: thickened mesenteric peritoneal surface (A) markedly reduced after






















Fig. 2. Histology of peritoneal biopsy infiltrated by pancreatic adenocarcinoma wi
after  PIPAC procedure showing marked regressive changes with fibrosis and rare sca
H&E,  B inset: immunoperoxidase).
2. Case presentation
A 55-year-old man  without co-morbidities was admitted to the
hospital in March 2017 with a left hemithorax stabbing pain. An
abdominal CT scan showed ascites and multiple peritoneal nodules
and inhomogeneity of the pancreas isthmus associated with slight
dilation of the main pancreatic duct.
The histological examination from CT-guided biopsy of peri-
toneal nodule showed metastasis of adenocarcinoma of pancreatic
origin. CEA was 1.7 ng/mL (n.v. < 5), Ca 19.9 was 4553.6 IU/mL (n.v.
< 37).
Given the extent of disease, we carried out a combination of
systemic chemotherapy with fluorouracil, leucovorin, irinotecan,
and oxaliplatin (FOLFIRINOX) of which 13 cycles were completed
until an adverse reaction to oxaliplatin.
The abdomen CT scans performed at the end of the first-line
chemotherapy showed a partial response, both on primary tumor
and peritoneum (Fig. 1).
In February 2018, encouraged by the good response, the mul-
tidisciplinary tumor board (MDT) proposed to integrate systemic
FOLFIRI (folinic acid, fluorouracil, and irinotecan) with PIPAC (UIN:
researchregistry6039).
At admission before surgery, the patient had a good general con-
dition (Eastern Cooperative Oncology Group performance status
grade 0). Laboratory tests were within normal limits.
b
t
S76significant histological regressive changes to chemotherapy (A). Peritoneal biopsy
 individual tumor cells (B) positive at immunostaining for BerEP4 (inset) (A and B:
The PIPAC procedure was first performed in February 2018,
ccording to the standard technique [17]. After laparoscopy and
valuation of PM extent according to the Sugarbaker Peritoneal
ancer Index (PCI), any ascitic fluid is drained and at least four peri-
oneal biopsies are taken for chemotherapy-response assessment.
onnecting a nebulizer (Capnopen-MIP, Reger Medizintechnik,
ottweil, Germany) to a high-pressure injector (Injektron 82 M,
edTron, Saarbruecken), a pressurized aerosol containing antiblas-
ic drugs is administered inside the peritoneal cavity.
The procedure is monitored by the laparoscopic camera hold
n place by a self-retaining retractor and the injection is remote-
ontrolled to avoid occupational exposure. After maintaining the
apnoperitoneum for 30 min  at 37 ◦C, the aerosol is evacuated via
 closed aerosol waste system. The trocars are removed, and no
bdominal drain tube is applied. The fascia and skin are closed with
bsorbable sutures.
Chemotherapy agents for PIPAC administration were chosen
ased on previous drug exposure, adverse reaction, and response
o systemic chemotherapy. We  decided for the combination of cis-
latin 7.5 mg/m2  in 150 mL  NaCl solution and doxorubicin 1.5
g/m2  in 50 mL  NaCl.
At the first PIPAC, the Peritoneal Cancer Index (PCI), calculated
ccording to Sugarbaker’s criteria [18] revealed a score of 22. The
aseline pathological response on peritoneal biopsies according to
he Peritoneal Regression Grading Score (PRGS) [19] was  2. There
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were no postoperative adverse events and the patient was  dis-
charged on the second postoperative day.
The patient repeated 3 more PIPAC-CD cycles every 6–8 weeks:
April 2018 (PCI 22, PRGS 1), June 2018 (PCI 22, PRGS 1), and August
2018 (PCI 29, PRGS 2) (Fig. 2).
All the cycles were very well tolerated, and no postoperative
complications were noted. FOLFIRI was continued between PIPAC
administrations with 2 weeks interval before and one week after
each PIPAC cycle.
Global Health Score/QoL of the EORTC quality of life question-
naire (QLQ-C30) before PIPAC was 92, it maintained stable after 2
PIPAC cycles and slightly decreased to 83 after the fourth PIPAC.
The abdomen CT scan performed in September 2018 showed a
progression of peritoneal disease.
Comprehensive genomic profiling of peritoneal tumor samples
documented the negativity of Ribonucleotide Reductase Catalytic
Subunit M1  (RRM1) on immunochemistry. On this base, a new line
of systemic chemotherapy with gemcitabine was started 18 months
after diagnosis.
In July 2019 the patient developed initial symptoms of intestinal
sub-occlusion and the new CT scan showed further progression of
the disease. Symptomatic and supportive care was therefore initi-
ated.
The patient died in December 2019, 33 months after the diag-
nosis.
3. Discussion
Peritoneal dissemination from PDAC confers a dismal progno-
sis as available treatment relies on systemic chemotherapy that
roughly reaches 1-year survival and it is affected by severe side
effects [6,7].
We report our first case of multimodal treatment for PM of pan-
creatic origin, illustrating the possibility to safely administer PIPAC
and systemic chemotherapy with a good tolerance profile.
Considering the good response to FOLFIRINOX on primary tumor
and PM,  switched to FOLFIRI because of an adverse reaction to oxali-
platin, the MDT  proposed to combine systemic administration with
PIPAC-CD.
We experienced no intraoperative and postoperative complica-
tions and toxicity was not a concern, as we did not observe any
renal, hepatic, or bone marrow impairment. After each PIPAC, the
patient was discharged within the second postoperative day.
Importantly, during treatment, the patient experienced an opti-
mal  quality of life, with a slight decrease in the Global Health
Score/QoL score of QLQ-C30 after the fourth cycle. The combination
of intravenous and locoregional chemotherapy seems feasible, as
most of the systemic chemotherapy regimens fit well with a PIPAC
administration every 6–8 weeks. In the present case, we  experi-
enced no delay in the resumption of systemic FOLFIRI after PIPAC
and vice versa. Furthermore, the patient tolerated well the whole
treatment schedule, not only managing daily activities but also
being able to undertake working duties as well as flying between
Europe and North America.
The possibility to repeat this non-complicated, minimally
invasive procedure allowed therapy-response monitoring on sub-
sequent biopsies. PRGS reduction after the first two PIPAC cycles
demonstrated a pathological response on peritoneal metastases
after the addition of locoregional chemotherapy, attesting the
anti-tumoral efficacy of PIPAC. Also, when dealing with PM,  a patho-
logical assessment is a very attractive feature considering that
radiological imaging poorly performs on measurable peritoneal
nodules volume reduction and PCI evaluation it is not reliable on
fibrotic nodules. Remarkably, peritoneal biopsies offer the opportu-
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ay  provide evidence of further effective therapeutic options. In
his case, the absence of Ribonucleotide Reductase Catalytic Sub-
nit M1  (RRM1) in survivor cell lines led to a tailored shift to
emcitabine systemic chemotherapy [20].
Of course, this is only a single case and several factors con-
ributed to the outcomes observed, however, the overall survival of
3 months is promising for this metastatic neoplasm and encour-
ges further research on the described multimodal approach for
eritoneal dissemination of pancreatic origin. Furthermore, the
epeated response assessment and molecular characterization on
ubsequent biopsies may shed new insights on the natural history
f pancreatic cancer, paving the way for personalized medicine.
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